1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Bullous Pemphigoid - Pipeline Review, H1 2013

Bullous Pemphigoid - Pipeline Review, H1 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 35 pages

Bullous Pemphigoid - Pipeline Review, H1 2013


Summary


Global Markets Direct’s, 'Bullous Pemphigoid - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Bullous Pemphigoid, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bullous Pemphigoid. Bullous Pemphigoid - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope


- A snapshot of the global therapeutic scenario for Bullous Pemphigoid.
- A review of the Bullous Pemphigoid products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Bullous Pemphigoid pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.


Reasons to buy


- Identify and understand important and diverse types of therapeutics under development for Bullous Pemphigoid.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Bullous Pemphigoid pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Bullous Pemphigoid - Pipeline Review, H1 2013
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Bullous Pemphigoid Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Bullous Pemphigoid 7
Bullous Pemphigoid Therapeutics under Development by Companies 9
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Discovery and Pre-Clinical Stage Products 14
Comparative Analysis 14
Bullous Pemphigoid Therapeutics - Products under Development by Companies 15
Companies Involved in Bullous Pemphigoid Therapeutics Development 16
Novartis AG 16
iCo Therapeutics Inc. 17
Nihon Pharmaceutical Industry Co., Ltd. 18
Bullous Pemphigoid - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 23
Drug Profiles 26
bertilimumab - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
NPB-01 - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
QGE-031 - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
Drug For Autoimmune Disorders - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
V-2248 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Bullous Pemphigoid Therapeutics - Drug Profile Updates 35
Bullous Pemphigoid Therapeutics - Dormant Products 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 39
Disclaimer 39

List of Tables


Number of Products Under Development for Bullous Pemphigoid, H1 2013 7
Products under Development for Bullous Pemphigoid - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 10
Comparative Analysis by Late Stage Development, H1 2013 11
Comparative Analysis by Mid Clinical Stage Development, H1 2013 12
Comparative Analysis by Early Clinical Stage Development, H1 2013 13
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 14
Products under Development by Companies, H1 2013 15
Novartis AG, H1 2013 16
iCo Therapeutics Inc., H1 2013 17
Nihon Pharmaceutical Industry Co., Ltd., H1 2013 18
Assessment by Monotherapy Products, H1 2013 19
Assessment by Stage and Route of Administration, H1 2013 22
Assessment by Stage and Molecule Type, H1 2013 25
Bullous Pemphigoid Therapeutics - Drug Profile Updates 35
Bullous Pemphigoid Therapeutics - Dormant Products 37

List of Figures


Number of Products under Development for Bullous Pemphigoid, H1 2013 7
Products under Development for Bullous Pemphigoid - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Late Stage Products, H1 2013 11
Mid Clinical Stage Products, H1 2013 12
Early Clinical Stage Products, H1 2013 13
Discovery and Pre-Clinical Stage Products, H1 2013 14
Assessment by Monotherapy Products, H1 2013 19
Assessment by Route of Administration, H1 2013 20
Assessment by Stage and Route of Administration, H1 2013 21
Assessment by Molecule Type, H1 2013 23
Assessment by Stage and Molecule Type, H1 2013 24

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2016

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Nuclear Factor Erythroid 2 Related ...

Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Pipeline Review, H2 2016

Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen ...

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016’, ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.